Literature DB >> 20679181

HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats.

Jeffrey P Cardinale1, Srinivas Sriramula, Romain Pariaut, Anuradha Guggilam, Nithya Mariappan, Carrie M Elks, Joseph Francis.   

Abstract

Reactive oxygen species and proinflammatory cytokines contribute to cardiovascular diseases. Inhibition of downstream transcription factors and gene modifiers of these components are key mediators of hypertensive response. Histone acetylases/deacetylases can modulate the gene expression of these hypertrophic and hypertensive components. Therefore, we hypothesized that long-term inhibition of histone deacetylase with valproic acid might attenuate hypertrophic and hypertensive responses by modulating reactive oxygen species and proinflammatory cytokines in SHR rats. Seven-week-old SHR and WKY rats were used in this study. Following baseline blood pressure measurement, rats were administered valproic acid in drinking water (0.71% wt/vol) or vehicle, with pressure measured weekly thereafter. Another set of rats were treated with hydralazine (25 mg/kg per day orally) to determine the pressure-independent effects of HDAC inhibition on hypertension. Following 20 weeks of treatment, heart function was measured using echocardiography, rats were euthanized, and heart tissue was collected for measurement of total reactive oxygen species, as well as proinflammatory cytokine, cardiac hypertrophic, and oxidative stress gene and protein expressions. Blood pressure, proinflammatory cytokines, hypertrophic markers, and reactive oxygen species were increased in SHR versus WKY rats. These changes were decreased in valproic acid-treated SHR rats, whereas hydralazine treatment only reduced blood pressure. These data indicate that long-term histone deacetylase inhibition, independent of the blood pressure response, reduces hypertrophic, proinflammatory, and hypertensive responses by decreasing reactive oxygen species and angiotensin II type1 receptor expression in the heart, demonstrating the importance of uncontrolled histone deacetylase activity in hypertension.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20679181      PMCID: PMC2931819          DOI: 10.1161/HYPERTENSIONAHA.110.154567

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  44 in total

1.  LPS regulates proinflammatory gene expression in macrophages by altering histone deacetylase expression.

Authors:  Hnin Thanda Aung; Kate Schroder; Stewart R Himes; Kristian Brion; Wendy van Zuylen; Angela Trieu; Harukazu Suzuki; Yoshihide Hayashizaki; David A Hume; Matthew J Sweet; Timothy Ravasi
Journal:  FASEB J       Date:  2006-07       Impact factor: 5.191

2.  Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy.

Authors:  Yongli Kong; Paul Tannous; Guangrong Lu; Kambeez Berenji; Beverly A Rothermel; Eric N Olson; Joseph A Hill
Journal:  Circulation       Date:  2006-05-30       Impact factor: 29.690

3.  Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes.

Authors:  Chang-Shi Chen; Shu-Chuan Weng; Ping-Hui Tseng; Ho-Pi Lin; Ching-Shih Chen
Journal:  J Biol Chem       Date:  2005-09-26       Impact factor: 5.157

Review 4.  Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease.

Authors:  Carlos M Ferrario; William B Strawn
Journal:  Am J Cardiol       Date:  2006-05-09       Impact factor: 2.778

5.  Chronic central GABAergic stimulation attenuates hypothalamic hyperactivity and development of spontaneous hypertension in rats.

Authors:  S Sasaki; T Nakata; S Kawasaki; J Hayashi; M Oguro; K Takeda; M Nakagawa
Journal:  J Cardiovasc Pharmacol       Date:  1990-05       Impact factor: 3.105

Review 6.  Redox signaling in hypertension.

Authors:  Tamara M Paravicini; Rhian M Touyz
Journal:  Cardiovasc Res       Date:  2006-05-09       Impact factor: 10.787

7.  Molecular mechanism of angiotensin II type I and type II receptors in cardiac hypertrophy of spontaneously hypertensive rats.

Authors:  N Makino; M Sugano; S Otsuka; T Hata
Journal:  Hypertension       Date:  1997-10       Impact factor: 10.190

8.  Inhibition of NF-kappaB induces regression of cardiac hypertrophy, independent of blood pressure control, in spontaneously hypertensive rats.

Authors:  Sudhiranjan Gupta; David Young; Subha Sen
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-03-04       Impact factor: 4.733

9.  Concurrent opposite effects of trichostatin A, an inhibitor of histone deacetylases, on expression of alpha-MHC and cardiac tubulins: implication for gain in cardiac muscle contractility.

Authors:  Francesca J Davis; Jyothish B Pillai; Madhu Gupta; Mahesh P Gupta
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-09-23       Impact factor: 4.733

10.  Tumor necrosis factor activates angiotensinogen gene expression by the Rel A transactivator.

Authors:  A R Brasier; J Li; K A Wimbish
Journal:  Hypertension       Date:  1996-04       Impact factor: 10.190

View more
  82 in total

Review 1.  Epigenetic Mechanisms and Hypertension.

Authors:  Mingyu Liang
Journal:  Hypertension       Date:  2018-12       Impact factor: 10.190

2.  The effect of sodium valproate on acetic acid-induced colitis in rats.

Authors:  Ali Najafi; Ehsan Motaghi; Mohammad Javad Hosseini; Masoumeh Ghasemi-Pirbaluti
Journal:  Inflammopharmacology       Date:  2016-12-31       Impact factor: 4.473

3.  Epigenetic regulation of the electrophysiological phenotype of human embryonic stem cell-derived ventricular cardiomyocytes: insights for driven maturation and hypertrophic growth.

Authors:  Maggie Zi Ying Chow; Lin Geng; Chi-Wing Kong; Wendy Keung; Jacky Chun-Kit Fung; Kenneth R Boheler; Ronald A Li
Journal:  Stem Cells Dev       Date:  2013-06-14       Impact factor: 3.272

4.  Lysine deacetylase inhibition attenuates hypertension and is accompanied by acetylation of mineralocorticoid receptor instead of histone acetylation in spontaneously hypertensive rats.

Authors:  Young Mi Seok; Hae Ahm Lee; Kwon Moo Park; Mi-Hyang Hwangbo; In Kyeom Kim
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-04-22       Impact factor: 3.000

Review 5.  Emerging roles for histone deacetylases in pulmonary hypertension and right ventricular remodeling (2013 Grover Conference series).

Authors:  Maria A Cavasin; Kurt R Stenmark; Timothy A McKinsey
Journal:  Pulm Circ       Date:  2015-03       Impact factor: 3.017

Review 6.  Histone Deacetylases and Cardiometabolic Diseases.

Authors:  Kan Hui Yiew; Tapan K Chatterjee; David Y Hui; Neal L Weintraub
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-07-16       Impact factor: 8.311

7.  3-Hydroxypyridin-2-thione as novel zinc binding group for selective histone deacetylase inhibition.

Authors:  Vishal Patil; Quaovi H Sodji; James R Kornacki; Milan Mrksich; Adegboyega K Oyelere
Journal:  J Med Chem       Date:  2013-04-18       Impact factor: 7.446

8.  Class I HDAC imaging using [ (3)H]CI-994 autoradiography.

Authors:  Yajie Wang; Yan-Ling Zhang; Krista Hennig; Jennifer P Gale; Yijia Hong; Anna Cha; Misha Riley; Florence Wagner; Stephen J Haggarty; Edward Holson; Jacob Hooker
Journal:  Epigenetics       Date:  2013-06-11       Impact factor: 4.528

9.  Role of the histone deacetylase inhibitor valproic acid in high-fat diet-induced hypertension via inhibition of HDAC1/angiotensin II axis.

Authors:  J Choi; S Park; T K Kwon; S I Sohn; K M Park; J I Kim
Journal:  Int J Obes (Lond)       Date:  2017-07-19       Impact factor: 5.095

10.  Valproic acid: an anticonvulsant drug with potent antinociceptive and anti-inflammatory properties.

Authors:  José Christian Machado Ximenes; Danilo de Oliveira Gonçalves; Rafaelly Maria Pinheiro Siqueira; Kelly Rose Tavares Neves; Gilberto Santos Cerqueira; Alyne Oliveira Correia; Francisco Hélder Cavalcante Félix; Luzia Kalyne Almeida Moreira Leal; Gerly Anne de Castro Brito; Maria da Graça Naffah-Mazzacorati; Glauce Socorro de Barros Viana
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-14       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.